Search research articles
Contact Us
Filters
Showing results (21-30 of 127) with videos related to
Page
of 13
Sort By:
Computational Toxicology (Amsterdam, Netherlands)
|
February 12, 2019
Homology models of mouse and rat estrogen receptor-<i>α</i> ligand-binding domain created by <i>in silico</i> mutagenesis of a human template: molecular docking with 17ß-estradiol, diethylstilbestrol, and paraben analogs
Thomas L Gonzalez, James M Rae, Justin A Colacino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer
James M Rae, Meredith Regan, Brian Leyland-Jones, et al.
Physiological Genomics
|
December 8, 2017
Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
Jacqueline M Dempsey, Jingyue Xi, N Lynn Henry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 10, 2009
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Michaela J Higgins, James M Rae, David A Flockhart, et al.
Breast Cancer Research and Treatment
|
March 30, 2012
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
Matthew J Sikora, Viktoriya Strumba, Marc E Lippman, et al.
Breast Cancer Research and Treatment
|
April 17, 2016
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Cameron P Capper, José M Larios, Matthew J Sikora, et al.
Breast Cancer Research and Treatment
|
September 28, 2006
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research
James M Rae, Chad J Creighton, Jeanne M Meck, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 4, 2004
Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms
Erin Harleton, Marie Webster, Namandjé N Bumpus, et al.
Cancer Research
|
April 6, 2006
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors
Chad J Creighton, Amy M Hilger, Shalini Murthy, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 14, 2008
The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6
Natasha T Snider, Matthew J Sikora, Chitra Sridar, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 127) with videos related to
Sort By:
Page
of 13
Computational Toxicology (Amsterdam, Netherlands)
|
February 12, 2019
Homology models of mouse and rat estrogen receptor-<i>α</i> ligand-binding domain created by <i>in silico</i> mutagenesis of a human template: molecular docking with 17ß-estradiol, diethylstilbestrol, and paraben analogs
Thomas L Gonzalez, James M Rae, Justin A Colacino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer
James M Rae, Meredith Regan, Brian Leyland-Jones, et al.
Physiological Genomics
|
December 8, 2017
Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
Jacqueline M Dempsey, Jingyue Xi, N Lynn Henry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 10, 2009
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Michaela J Higgins, James M Rae, David A Flockhart, et al.
Breast Cancer Research and Treatment
|
March 30, 2012
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
Matthew J Sikora, Viktoriya Strumba, Marc E Lippman, et al.
Breast Cancer Research and Treatment
|
April 17, 2016
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Cameron P Capper, José M Larios, Matthew J Sikora, et al.
Breast Cancer Research and Treatment
|
September 28, 2006
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research
James M Rae, Chad J Creighton, Jeanne M Meck, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 4, 2004
Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms
Erin Harleton, Marie Webster, Namandjé N Bumpus, et al.
Cancer Research
|
April 6, 2006
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors
Chad J Creighton, Amy M Hilger, Shalini Murthy, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 14, 2008
The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6
Natasha T Snider, Matthew J Sikora, Chitra Sridar, et al.
Page
of 13